VNRX · Company research

VolitionRx Limited (VNRX): Stock News & Events

Recent company-linked news records available in the database.

RESEARCH CONTEXT

Understand the numbers

Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.

17records availableHealthcare

Stock News & Events data

Database-backed records only

17 rows
titlesummaryurlsourcepublished atsentimentsentiment scorerelevance score
VolitionRx (NYSEAM:VNRX) - Stock Analysis - Simply Wall StreetVolitionRx (NYSEAM:VNRX) - Stock Analysis Simply Wall StreetView source ↗Simply Wall StreetOct 11, 2026neutral00.6
No shares were sold as VolitionRx (VNRX) retained 608 COO shares for cancellation to cover taxes. - Stock TitanNo shares were sold as VolitionRx (VNRX) retained 608 COO shares for cancellation to cover taxes. Stock TitanView source ↗Stock TitanSep 30, 2026neutral00.6
Neither party sold shares as VolitionRx (VNRX) retained 284 shares for its commercial chief’s taxes. - Stock TitanNeither party sold shares as VolitionRx (VNRX) retained 284 shares for its commercial chief’s taxes. Stock TitanView source ↗Stock TitanSep 30, 2026neutral00.6
VolitionRx Uses Private Equity Issuance to Reduce Debt - The Globe and MailVolitionRx Uses Private Equity Issuance to Reduce Debt The Globe and MailView source ↗The Globe and MailSep 26, 2026neutral00.6
A €6.3 million French program will test one blood marker to spot sepsis early - Stock TitanA €6.3 million French program will test one blood marker to spot sepsis early Stock TitanView source ↗Stock TitanSep 17, 2026neutral00.6
On Friday, there are stocks with unusual volume. Let's take a look. - ChartMillOn Friday, there are stocks with unusual volume. Let's take a look. ChartMillView source ↗ChartMillAug 28, 2026neutral00.6
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations - Yahoo FinancePenny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations Yahoo FinanceView source ↗Yahoo FinanceAug 27, 2026neutral00.6
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations - BenzingaPenny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations BenzingaView source ↗BenzingaAug 27, 2026neutral00.6
Thursday's session: gap up and gap down stocks - ChartMillThursday's session: gap up and gap down stocks ChartMillView source ↗ChartMillAug 27, 2026neutral00.6
Volition's sepsis biomarker predicts 28-day death and kidney treatment needs - Stock TitanVolition's sepsis biomarker predicts 28-day death and kidney treatment needs Stock TitanView source ↗Stock TitanAug 26, 2026neutral00.6
VolitionRx call will cover Q2 results and upcoming milestones - Stock TitanVolitionRx call will cover Q2 results and upcoming milestones Stock TitanView source ↗Stock TitanAug 11, 2026neutral00.6
VNRX Forecast — Price Target — Prediction for 2027 - TradingViewVNRX Forecast — Price Target — Prediction for 2027 TradingViewView source ↗TradingViewJun 25, 2026neutral00.6
VolitionRx stock tumbles on $4.6M offering priced at discount - Investing.comVolitionRx stock tumbles on $4.6M offering priced at discount Investing.comView source ↗Investing.comJun 8, 2026neutral00.6
VolitionRx Limited (VNRX): 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts - Yahoo FinanceVolitionRx Limited (VNRX): 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts Yahoo FinanceView source ↗Yahoo FinanceMay 24, 2026neutral00.6
$VNRX stock is down 15% today. Here's what we see in our data. - Quiver Quantitative$VNRX stock is down 15% today. Here's what we see in our data. Quiver QuantitativeView source ↗Quiver QuantitativeApr 2, 2026neutral00.6
VNRX Stock Soars 34% Pre-Market — What's Driving The Rally? - StocktwitsVNRX Stock Soars 34% Pre-Market — What's Driving The Rally? StocktwitsView source ↗StocktwitsMar 25, 2026neutral00.6
Why Is VNRX Stock Soaring Over 30% Today? - StocktwitsWhy Is VNRX Stock Soaring Over 30% Today? StocktwitsView source ↗StocktwitsMar 18, 2026neutral00.6

Informational research only, not financial advice. Forecasts are uncertain and can be wrong.